Anti-PSA (Prostate-Specific Antigen) antibodies are widely used in clinical diagnostics for detecting and monitoring prostate cancer. PSA is a protein produced by both normal and malignant cells of the prostate gland and is typically present at low levels in the blood of healthy men. Elevated PSA levels may indicate prostate cancer, benign prostatic hyperplasia (BPH), or inflammation of the prostate. Anti-PSA antibodies are commonly employed in ELISA and immunohistochemistry (IHC) to detect PSA in serum or tissue samples.

They help in early diagnosis, disease progression monitoring, and evaluating the effectiveness of treatment. In research, these antibodies aid in studying prostate biology and cancer pathogenesis. They are critical in differentiating prostatic tissues from non-prostatic ones, especially in cases involving metastases of unknown origin. Anti-PSA assays are one of the most established biomarker-based diagnostics in male oncology and remain a vital component in prostate health screening programs globally.